ChromaDex (NASDAQ:CDXC – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $8.00 to $11.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 39.24% from the company’s current price.
Other analysts have also recently issued research reports about the stock. LADENBURG THALM/SH SH raised their target price on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 6th.
Check Out Our Latest Stock Analysis on ChromaDex
ChromaDex Stock Performance
Insider Buying and Selling at ChromaDex
In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now directly owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 9.64% of the company’s stock.
Institutional Investors Weigh In On ChromaDex
Several hedge funds and other institutional investors have recently made changes to their positions in CDXC. D. E. Shaw & Co. Inc. grew its holdings in shares of ChromaDex by 1,785.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock valued at $5,365,000 after purchasing an additional 957,665 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of ChromaDex by 288.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock valued at $3,517,000 after purchasing an additional 492,148 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of ChromaDex by 189.0% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 506,186 shares of the company’s stock valued at $2,685,000 after purchasing an additional 331,014 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of ChromaDex during the 4th quarter valued at approximately $1,647,000. Finally, Renaissance Technologies LLC grew its holdings in shares of ChromaDex by 68.0% during the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock valued at $3,781,000 after purchasing an additional 288,588 shares during the last quarter. 15.41% of the stock is owned by institutional investors.
About ChromaDex
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Further Reading
- Five stocks we like better than ChromaDex
- How to Calculate Stock Profit
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Why Are Stock Sectors Important to Successful Investing?
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Dividend Capture Strategy: What You Need to Know
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.